Dr. Amelie Gubitz joined the NINDS in 2006 and currently serves as a Program Director in the Neurodegeneration Cluster. Her portfolio includes basic, translational and clinical research in amyotrophic lateral sclerosis and X-linked spinal and bulbar muscular atrophy (Kennedy's Disease). Dr. Gubitz earned a Ph.D. in pharmacology from the University of Cambridge, UK, and then completed a Wellcome Trust fellowship at Harvard Medical School in circadian biology. Subsequently, she worked as a Senior Scientist in the target discovery group for neuropathic pain at Parke Davis, UK. In 2000, Dr. Gubitz joined the Department of Biochemistry and Biophysics at the University of Pennsylvania, first as a postdoctoral research associate and later as Research Assistant Professor, where she studied the disease mechanisms of spinal muscular atrophy, a motor neuron-degenerative disorder, and developed a translational research program for the disease. Dr. Gubitz previously served as a Program Analyst in the Neurogenetics Cluster at the NINDS. In this role, she was involved in managing a research resource project for the generation of genetically engineered mouse models and a preclinical drug development program for spinal muscular atrophy.
Last Modified June 30, 2011